Hub and Spoke, Comparative Outcomes for Parkinson's Disease Treated With Deep Brain Stimulation (Hub&Spoke)
調査の概要
詳細な説明
The proposed outcomes study is a prospective, randomized, multicenter, single blind, non-inferiority clinical trial comparing the safety and efficacy of deep brain stimulation therapy applied in a community-based model for 62 subjects with Parkinson's disease appropriate for STN DBS therapy.
Eight community-based private neurology practices will be networked to Vanderbilt University Medical Center (VUMC). Neurologists for each practice will attend structured educational programs offered by Medtronic in the identification, selection, and management of Parkinson's disease patients with DBS therapy. Following this educational program, each practice will identify subjects for implantation VUMC. Following screening and baseline visits at VUMC, appropriate patients will be implanted with bilateral subthalamic nucleus deep brain stimulating therapy. The initial post-operative programming will be done at VUMC four weeks after implantation. 8 subjects will then be equally randomized with half being followed for long-term management by the community-based neurologist. The other half will be followed at VUMC.
All subsequent outpatient evaluation management of medications and deep brain stimulation will be managed per standard of care at the location assigned by randomization, community-based private neurology practice or VUMC.
All subjects will be enrolled during the first 24 months of the study. Follow-up evaluations at 12 months will be performed at VUMC. Each patient identified by the community-based neurologist for implantation will be assessed at VUMC. This assessment will include a videotaped off and on UPDRS III rating, neuropsychological testing, and appropriateness as outlined in the patient selection educational program. Patients will be implanted by bilateral subthalamic nucleus deep brain stimulation therapy within 120 days of their initial assessment. The initial post-operative programming will be performed four weeks post-operatively, this is all standard of care.
Subjects will then be randomized to be either managed by their community-based neurologist or at VUMC. Follow-up evaluations at 12 months will include a videotaped on and off UPDRS rating and neuropsychological testing, anti-parkinson medication dosages, and quality of life measures.
研究の種類
段階
- 適用できない
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients must have a clinical diagnosis of probable idiopathic PD. The diagnosis will be based upon the presence of at least three of four clinical features according to diagnostic utility (Resting Tremor, Bradykinesia, Rigidity, Asymmetric Onset) and an absence of clinical features suggestive of an alternative diagnosis.
- Demonstrated response to dopaminergic therapy. In order to exclude patients with a possible alternative diagnosis, all subjects included in the study must have demonstrated a good response to DA drugs, defined as demonstrating at least 30% improvement in parkinsonian motor signs, based upon the UPDRS motor examination subscore, following the administration of their DA drug(s) during the screening neurological examination.
- Advanced Parkinson's disease.
- No contraindications to surgery.
- Age between 50 and 75 years old.
- Available for follow-up for the entire duration of the study.
- Informed Consent: The subject understands the risks, benefits, and alternatives to the study procedures and participation in the study.
- MRI within normal range for age
Exclusion Criteria:
- Evidence of an alternative diagnosis or secondary parkinsonism, as suggested by features unusual early in the clinical course: Prominent postural instability, freezing phenomena, or hallucinations unrelated to medications in the first 3 years after symptom onset; dementia preceding motor symptoms; supranuclear gaze palsy (other than restriction of upward gaze) or slowing of vertical saccades in the first year; severe, symptomatic dysautonomia unrelated to medications; documentation of a condition known to produce parkinsonism and plausibly connected to the subject's symptoms (such as suitably located focal brain lesions or neuroleptic use within the past 6 months)
- Uncontrolled medical condition or clinically significant medical disease that would increase the risk of developing pre- or postoperative complications (e.g., significant cardiac or pulmonary disease, uncontrolled hypertension).
- Evidence of dementia
- Major psychiatric disorder
- Previous brain operation or injury.
- Active participation in another clinical trial for the treatment of PD.
- Patients who have demand cardiac pacemakers or who have medical conditions that require repeat MRI scans.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
アクティブコンパレータ:Movement Disorder Center
Device programming, Deep Brain stimulator will be programmed at the implanting center, standard of care
|
Deep Brain Stimulator will be programmed with at the implanting movement disorders center
|
実験的:Programming by community Neurologist
Device programming, Deep Brain Stimulator will be programmed by community Neurologist
|
Deep Brain stimulator with be programmed by a community Neurologist
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
UPDRS part IV
時間枠:one year
|
Change in score from baseline, complication of medical therapy for Parkinson's disease
|
one year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
UPDRS
時間枠:One Year
|
Change from baseline, composite score of all 4 parts of the UPDRS
|
One Year
|
PDQ-39
時間枠:One year
|
Change from baseline in quality of life
|
One year
|
Obeso Dyskinesia Rating Scale
時間枠:One year
|
Change from baseline, involuntary movements caused by Parkinson's disease treatment
|
One year
|
Hoehn and Yahr rating
時間枠:One year
|
Change from baseline, in stage of disease
|
One year
|
Schwab and England ADL score
時間枠:One year
|
Change from baseline, signs and symptoms of depression
|
One year
|
Parkinson's medication in LEDD
時間枠:One year
|
Change from baseline in total Parkinson's disease medications
|
One year
|
DBS voltage/current
時間枠:One year
|
One year settings of DBS system
|
One year
|
DBS electrode configuration
時間枠:One year
|
One year settings of DBS system
|
One year
|
DBS pulse width
時間枠:one year
|
One year settings of DBS system
|
one year
|
DBS frequency
時間枠:one year
|
One year settings of DBS system
|
one year
|
協力者と研究者
スポンサー
協力者
捜査官
- 主任研究者:Fenna T Phibbs, MD、Vanderbilt Univeristy Medical Center
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
パーキンソン病の臨床試験
-
Adelphi Values LLCBlueprint Medicines Corporation完了肥満細胞性白血病 (MCL) | 攻撃的な全身性肥満細胞症 (ASM) | SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD) | くすぶり全身性肥満細胞症 (SSM) | 無痛性全身性肥満細胞症 (ISM) ISM サブグループが完全に募集されましたアメリカ
Standard of careの臨床試験
-
Compedica IncProfessional Education and Research Institute募集
-
DeRoyal Industries, Inc.Lincoln Memorial University完了皮膚感作 | 機械的、熱的、および放射線刺激に対する皮膚反応アメリカ
-
University of PittsburghShadyside Hospital Foundation完了
-
Saint-Joseph University完了
-
Johns Hopkins UniversityJuvenile Diabetes Research Foundation; National Eye Institute (NEI)募集
-
Johns Hopkins UniversityNational Eye Institute (NEI)完了